Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), sold a total of 12,274 shares of common stock over a three-day span, filings with the Securities and Exchange Commission show. The transactions, reported on a Form 4, took place from March 17 through March 19, 2026, and together generated proceeds of $839,069.
The sale was executed in three separate trades. On March 17, Whitfield sold 4,029 shares at $69.42 per share. The following day she disposed of 4,071 shares at $68.71 each. On March 19, she sold 4,174 shares at $67.00 per share. After these dispositions, Whitfield’s direct holdings stand at 35,028 shares of Tarsus Pharmaceuticals common stock.
The Form 4 filing identifies the purpose of the sales as tax withholding related to the vesting and settlement of Restricted Stock Units (RSUs). The transactions were carried out under Tarsus Pharmaceuticals’ policy that requires tax obligations arising from RSU vesting to be satisfied via a 'sell to cover' transaction.
Market context around the trades shows the stock was trading at $66.75, below the prices Whitfield realized on her sales, and the company’s market capitalization was listed at $2.85 billion. An InvestingPro analysis included in the filing notes that Tarsus appears undervalued by certain measures, with analyst price targets ranging from $88 to $105. An InvestingPro tip cited in the filing further highlights that Tarsus has more cash than debt on its balance sheet, which may provide financial flexibility despite the company’s current unprofitability.
Separately, recent corporate reporting for the fourth quarter of 2025 highlighted a notable increase in revenue and profitability. Tarsus disclosed net product sales of $151.7 million for the quarter and $451.4 million for the full year, driven principally by its flagship product XDEMVY. Those figures were described in company materials as marking a pivotal period of growth.
Despite the robust revenue performance, the stock registered a modest decline in aftermarket trading following the earnings release. The filing also notes that analyst firms had not yet issued rating updates in response to the results. These developments were presented as part of the company’s recent activity and as observations on its current financial position.
The Form 4 provides a window into an executive-level liquidity event that the company says was mechanistically required to meet tax obligations tied to equity compensation. Beyond the mechanics of the 'sell to cover' trades, the filing reiterates company financial characteristics referenced above, including revenue growth, market valuation metrics cited by InvestingPro, and a cash position that exceeds debt.
No additional changes to insider ownership beyond the post-sale share total were indicated in the filing, and no analyst rating changes were reported in connection with these disclosures.